Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | APP | P05067 | 3/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.64 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.64 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.63 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.63 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27833553 | 1.00 | KDM4E (0.87) | KDM4ELMNAAKR1C3ALDH1A1PKM | |
| SCHEMBL5848038 | 1.00 | KDM4E (0.87) | KDM4ELMNAAKR1C3ALDH1A1PKM | |
| SCHEMBL1609268 | 0.92 | KDM4E (0.79) | KDM4ELMNAAKR1C3ALDH1A1APP | |
| SCHEMBL1608802 | 0.92 | KDM4E (0.79) | KDM4ELMNAAKR1C3ALDH1A1APP | |
| SCHEMBL1609269 | 0.92 | KDM4E (0.79) | KDM4ELMNAAKR1C3ALDH1A1APP | |
| SCHEMBL1608804 | 0.92 | KDM4E (0.79) | KDM4ELMNAAKR1C3ALDH1A1APP | |
| SCHEMBL11179981 | 0.91 | KDM4E (0.74) | KDM4ELMNAAKR1C3ALDH1A1APP | |
| SCHEMBL6034563 | 0.91 | KDM4E (0.78) | KDM4ELMNAAKR1C3ALDH1A1APP | |
| SCHEMBL6034559 | 0.91 | KDM4E (0.78) | KDM4ELMNAAKR1C3ALDH1A1APP | |
| SCHEMBL20586637 | 0.90 | KDM4E (0.72) | KDM4ELMNAAKR1C3ALDH1A1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026518-B2 | Resveratrol analogs | LAILA IMPEX (IN) | 2006-04-11 | — | — | US | disclosed |
| US-20040209951-A1 | Novel resveratrol analogs | LAILA IMPEX (IN) | 2004-10-21 | — | — | US | disclosed |
| WO-2004000302-A1 | NOVEL RESVERATROL ANALOGS | GOKARAJU GANGA RAJU (IN) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003029183-A1 | METHOD OF SYNTHESISING CHICORIC ACID | UNIVERSITE DE BORDEAUX I (FR) | 2003-04-10 | — | — | WO | disclosed |
| US-6048875-A | CARDIOVASCULAR DISORDERS; REDUCING THROMBOSIS | ADIR ET COMPAGNIE (FR) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209951-A1 | Novel resveratrol analogs | HRH1, CBR1, CBR3 | KDM4E 1415/4885LMNA 4337/4885AKR1C3 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.